Vertex receives chmp positive opinion for kalydeco® for the treatment of infants with cystic fibrosis ages 1 month and older

London--(business wire)--vertex pharmaceuticals (nasdaq: vrtx) today announced that the european medicines agency's (ema's) committee for medicinal products for human use (chmp) adopted a positive opinion for the label expansion of kalydeco® (ivacaftor) for the treatment of infants with cystic fibrosis (cf) ages 1 month to less than 4 months old who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: r117h, g551d, g1244e, g1349d, g178r, g5.
VRTX Ratings Summary
VRTX Quant Ranking